Primary Care

Psoriatic arthritis

Questions discussed in this category

How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?

Patient is already on topical high potency corticosteroids. Any updated safety data on IL-17, IL-23 in pregnancy?

2 Answers available

How do you approach managing nausea and GI side effects when initiating methotrexate?

5 Answers available

What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Bissonnette et al., PMID 38324484

2 Answers available

How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?

3 Answers available

Would you recommend avoiding use of bimekizumab in patients at higher risk of fungal infections such as patients with diabetes who are on SGLT-2 inhibitors which also increase the risk of fungal infections?

How will you counsel patients about the risk and what strategies will you use to mitigate the increased risk of fungal infections seen in the BE COMPL...

2 Answers available

Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?

3 Answers available

How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?

The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.

1 Answer available

Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?

Given the drug-drug interaction, do you monitor more closely for methotrexate toxicity, counsel on symptoms of methotrexate toxicity, or avoid the com...

2 Answers available

How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?

What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?

2 Answers available

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

1 Answer available

Would you consider a biologic or JAK inhibitor to manage active PsA in a patient on chronic antibiotic therapy if they had previously failed all conventional DMARDs (including apremilast)?

Patient is on antibiotics for chronic spinal hardware infection.

1 Answer available

Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?

2 Answers available

Are there any concerns utilizing apremilast for psoriatic arthritis in patients who are also taking roflumilast for COPD?

1 Answer available

What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?

1 Answer available

How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

4 Answers available

What has been your experience using apremilast to treat mild to moderate psoriatic arthritis not controlled with NSAIDs?

1 Answer available

Are there any known contraindications for IL-23 use in patients with psoriatic arthritis and CKD or ESRD?

1 Answer available

What disease activity measures do you find helpful in clinical practice for psoriatic arthritis/peripheral spondyloarthritis?

1 Answer available